<DOC>
	<DOCNO>NCT00983255</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics single rise multiple rise IV dose TR-701 FA determine absolute bioavailability oral TR-701 FA follow single oral IV dose administration healthy adult subject .</brief_summary>
	<brief_title>Ascending Dose Pharmacokinetic ( PK ) Absolute Bioavailability ( BA )</brief_title>
	<detailed_description>SAD/Part A . - All subject Pilot Cohort receive single infusion 50 mg TR-701 FA injection 250 cc saline 180 minute . - Subjects Cohort 1 randomize receive single infusion placebo 100 mg TR-701 FA injection 250 500 cc saline 60 120 minute . - Subjects Cohort 2 randomize receive single infusion placebo 200 mg TR-701 FA injection 250 500 cc saline 60 120 minute . - Subjects Cohort 3 randomize receive single infusion placebo 400 mg TR-701 FA injection 250 500 cc saline 60 120 minute . MAD/Part B - Subjects Cohort 4 randomize receive daily infusion placebo 200 mg TR-701 FA injection 250 cc saline 60 minute 7 day . - Subjects Cohort 5 randomize receive daily infusion placebo 300 mg TR-701 FA injection 250 cc saline 60 minute 7 day . BA/Part C - Subjects Cohort 6 receive single 60 minute infusion 200 mg TR-701 FA injection 250 cc saline singe oral dose 200 mg TR-701 FA tablet open-label crossover design . Venous Tolerability/Part D - Subjects Cohort 8 receive daily 60 minute infusion 200 mg TR-701 FA injection 250 cc saline 3 day daily placebo infusion 3 daysin blind crossover design .</detailed_description>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Torezolid phosphate</mesh_term>
	<mesh_term>Torezolid</mesh_term>
	<criteria>good health body mass index 20 29.9 kg/m2 female subject must post menopausal least 1 year , surgically sterile , abstinent agree use effective method birth control history clinical manifestation clinically significant disorder history hypersensitivity drug compound history stomach intestinal surgery resection history infection unexplained frequency severity history alcoholism drug addiction within 1 year use tobacco nicotinecontaining product within 6 month use alcohol , grapefruit , caffeine , high tyraminecontaining food beverage use medication pregnancy , lactation , breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>